This study tests a new treatment for a type of blood cancer in young patients called Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-like) B-cell acute lymphoblastic leukemia (B-ALL). It combines a new drug, blinatumomab, with other medicines like dasatinib or imatinib, and chemotherapy. Blinatumomab helps the immune system attack cancer cells. Dasatinib and imatinib stop cancer cells from growing by blocking certain proteins.

Study Highlights:

• Duration: Participation lasts about 2 years.
• Treatment: Involves several cycles of drugs, including chemotherapy and blinatumomab.
• Risks: Potential side effects include infections, and some may need to stay in the hospital for treatment.

Participants must be under 18 years old and newly diagnosed with the specified types of leukemia. They will receive various treatments including oral and intravenous medications, and possibly radiation therapy. Regular check-ups and tests, like blood and bone marrow samples, are part of the study to monitor progress and side effects.